16 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Infectious Diseases CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science
    • 5.0, 3 Ratings

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

    • 47 min
    Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

    Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

    Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

    • 46 min
    Stacey B. Trooskin, MD, PhD - HCV 20 x 20: A Screening Initiative to Increase Hepatitis C Testing, Diagnosis, and Linkage to Care in High-Risk Populations

    Stacey B. Trooskin, MD, PhD - HCV 20 x 20: A Screening Initiative to Increase Hepatitis C Testing, Diagnosis, and Linkage to Care in High-Risk Populations

    Go online to PeerView.com/QWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious disease discusses strategies for increasing testing, diagnosis, and linkage to care in individuals who are at high risk for hepatitis C infection. Upon completion of this activity, participants should be better able to: Identify persons for whom HCV testing is recommended, Utilize appropriate diagnostic testing strategies for HCV, Incorporate national guidelines for HCV testing and diagnosis into routine clinical practice, Develop effective follow-up, counseling, and quality care strategies for patients with a confirmed diagnosis of HCV

    • 21 min
    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC

    • 1 hr 30 min
    Donna E. Sweet, MD, AAHIVS, MACP - Creating an HIV Prevention–Certified Provider Workforce: A Training and Certificate Program Designed to Improve the Competencies of Providers to Deliver Comprehensive HIV Prevention

    Donna E. Sweet, MD, AAHIVS, MACP - Creating an HIV Prevention–Certified Provider Workforce: A Training and Certificate Program Designed to Improve the Competencies of Providers to Deliver Comprehensive HIV Prevention

    Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet’s personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider’s individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

    • 38 min
    Joshua D. Lee, MD, MSc - Caring for the Patient With Opioid Use Disorder in an Outpatient Setting: Overcoming the Barriers to Medication-Assisted Treatment

    Joshua D. Lee, MD, MSc - Caring for the Patient With Opioid Use Disorder in an Outpatient Setting: Overcoming the Barriers to Medication-Assisted Treatment

    Go online to PeerView.com/XXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in addiction medicine discusses opioid use disorder in the outpatient setting and overcoming the various barriers to patients receiving medication. Upon completion of this activity, participants should be better able to: Identify barriers to the implementation of medication-assisted treatment (MAT) for patients with opioid use disorder (OUD), Discuss the efficacy of treatment programs that include MAT for the management of OUD, Employ strategies to effectively and safely integrate MAT into the management of patients with OUD, to reduce opioid misuse and improve treatment retention, particularly in the outpatient setting

    • 40 min

Customer Reviews

5.0 out of 5
3 Ratings

3 Ratings

Top Podcasts In Science

Listeners Also Subscribed To